|
1. A method of treating a brain disease, disorder or a symptom thereof in a human patient in need of such treatment comprising administering a pharmaceutical composition to the patient, the pharmaceutical composition comprising about 5×105 to 5×109 human CD34+ stem cells, wherein the human stem cells are enriched with functional human exogenous mitochondria, wherein the brain disease or disorder is not a primary mitochondrial disease or disorder caused by a pathogenic mutation in mitochondrial DNA or by a pathogenic mutation in nuclear DNA encoding a mitochondrial protein; and wherein the disease or disorder is selected from the group consisting of Parkinson Disease (PD), Alzheimer Disease (AD), adrenoleukodystrophy (ALD), Huntington Disease (HD), Guillain Barre Syndrome (GBS), and autism.
|